A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Cancer of Pancreas, Colon Cancer, Solid Tumor, Cancer
A Phase 1 dose escalation study in patients with advanced solid tumors harboring KRAS G12C mutation to determine the maximum tolerated dose and recommended Phase II dose of HBI-2438 and characterize its pharmacokinetic profile.
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
-
California Cancer Associates for Research and Excellence, Inc. (cCare), Encinitas, California, United States, 92024
The Oncology Institute of Hope and Innovation, Glendale, California, United States, 91204
The Oncology Institute of Hope and Innovation, Long Beach, California, United States, 90805
The Oncology Institute of Hope and Innovation, Pasadena, California, United States, 91105
California Cancer Associates for Research and Excellence, Inc. (cCare), San Marcos, California, United States, 92069
The Oncology Institute of Hope and Innovation, Santa Ana, California, United States, 92705
Sarcoma Oncology, Santa Monica, California, United States, 90403
Innovative Clinical Research Institute (ICRI), Whittier, California, United States, 90603
The Oncology Institute of Hope and Innovation, Whittier, California, United States, 90603
BRCR Medical Center, Plantation, Florida, United States, 33322
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
HUYABIO International, LLC.,
Alberto Bessudo, MD, PRINCIPAL_INVESTIGATOR, California Cancer Associates for Research and Excellence, Inc. (cCare)
2025-08